Sato Yasushi | Drug Safety Research & Development Pfizer Global Research & Development Nagoya Laboratories
スポンサーリンク
概要
- SATO Yasushiの詳細を見る
- 同名の論文著者
- Drug Safety Research & Development Pfizer Global Research & Development Nagoya Laboratoriesの論文著者
関連著者
-
Horii Ikuo
Showa Univ. (department Of Biochemical Toxicology School Of Pharmaceutical Sciences)
-
Horii I
Drug Safety Research And Development Pfizer Global Research And Development Nagoya Laboratories. Pfi
-
Horii Ikuo
Pfizer Global Research & Development Nagoya Laboratories Pfizer Inc.
-
Yamada Hiroshi
Drug Safety Research & Development Pfizer Global Research & Development Nagoya Laboratories
-
Horii Ikuo
Worldwide Safety Sciences Pgrd Nagoya Laboratories Pfizer Inc.
-
Fujikawa Masaaki
Drug Safety Research & Development Pfizer Global Research & Development Nagoya Laboratories
-
Fujikawa Masaaki
Worldwide Safety Sciences Pfizer Global Research & Development Nagoya Laboratories Pfizer Japan
-
Horii Ikuo
Worldwide Safety Sciences Pfizer Global Research & Development Nagoya Laboratories Pfizer Inc.
-
Fujikawa Masaaki
Worldwide Safety Sciences Pfizer Global Research & Development Nagoya Laboratories Pfizer Japan
-
Horii Ikuo
Biochemical Toxicology School Of Pharmaceutical Sciences Showa University
-
Sato Yasushi
Drug Safety Research & Development Pfizer Global Research & Development Nagoya Laboratories
-
Yamada Hiroshi
Worldwide Safety Sciences Pfizer Global Research And Development Nagoya Laboratories Pfizer Japan In
-
IIDAKA Takeshi
Worldwide Safety Sciences, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Japan
-
HORII Ikuo
Worldwide Safety Sciences, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Japan
-
HORII IKUO
Drug Safety Evaluation, Nagoya Laboratories, Pfizer Global Research and Development
-
Iidaka Takeshi
Worldwide Safety Sciences Pgrd Nagoya Laboratories Pfizer Inc.
-
Yamamoto Toshinori
Drug Safety Research & Development Pfizer Global Research & Development Nagoya Laboratories
-
Yamamoto T
Showa Univ. Tokyo Jpn
-
Yamamoto Toshinori
Department Of Biochemical Toxicology School Of Pharmaceutical Sciences Showa University
-
Fujikawa Masaaki
worldwide safety sciences
-
Yamada Hiroshi
worldwide safety sciences
-
Shirai Maki
Worldwide Safety Sciences Pgrd Nagoya Laboratories Pfizer Inc.
-
Shirai Maki
Worldwide Safety Sciences Global Research & Development Nagoya Laboratories Pfizer Inc.
-
YAMADA Hiroshi
Drug Safety Research and Development, Nagoya Laboratories, Pfizer Japan Inc.
-
TOMIZAWA Kaori
Drug Safety Research & Development, Pfizer Global Research & Development, Nagoya Laboratories
-
FUJIKAWA Masaaki
Drug Safety Research & Development, Pfizer Global Research & Development, Nagoya Laboratories
-
SATO Yasushi
Drug Safety Research & Development, Pfizer Global Research & Development, Nagoya Laboratories
-
Sato Yasushi
Worldwide Safety Sciences, PGRD Nagoya Laboratories, Pfizer Inc.
-
Tomizawa Kaori
Drug Safety Research & Development Pfizer Global Research & Development Nagoya Laboratories
-
Yamamoto Toshinori
Departments Of Clinical Pharmacy And Pharmacognosy School Of Pharmaceutical Sciences Showa Universit
-
Horii Ikuo
Worldwide Safety Sciences
-
Yamamoto Toshinori
Drug Metabolism Laboratory Chugai Pharmaceutical Co. Ltd.
-
Hamada Y.
Drug Safety Research And Development Pfizer Global Research And Development Nagoya Laboratories. Pfi
-
Horii Ikuo
Drug Safety Evaluation Pfizer Global Research And Development
-
Horii Ikuo
Drug Safety Evaluation Global Research & Development Pfizer Inc.
-
Yamamoto Toshinori
Department Of Pharmacology Medical College Of Oita
-
Fujikawa Masaaki
World Wide Safety Sciences
-
Sato Yasushi
Drug Safety And Pharmacokinetics Laboratories Taisho Pharmaceutical Co. Ltd.
著作論文
- EVALUATION OF HUMAN HEPATOCYTE CHIMERIC MICE AS A MODEL FOR TOXICOLOGICAL INVESTIGATION USING PANOMIC APPROACHES : EFFECT OF ACETAMINOPHEN ON THE EXPRESSION PROFILES OF PROTEINS AND ENDOGENOUS METABOLITES IN LIVER, PLASMA AND URINE
- Introduction of the in vivo Mini-tox study as an effective tool to improve confidence in safety in the early stage of drug development (2) Effects of atypical antipsychotics X(Test methods, Proceedings of the 32nd Annual Meeting)